Table 1 Trial characteristics, exposure, baseline participant covariates, and outcomes across trials and treatment groups
From: Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Study | Duration | Total subjects | Antipsychotic | Total exposure: median (max) | % with weight gain drugs | Age: mean (SD) | PANSS: mean (SD) | % White | % Black | % Female | Outcome: % with 7% weight gain |
|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline characteristics | |||||||||||
1 | Variable (≤11 mts) | 206 | Paliperidone: 50.5% | 3.06 (21.30) | 9.6 | 39 (11) | 92.9 (11.2) | 60 | 8 | 44 | 18.27 |
Placebo: 49.5% | 0 | 10.8 | 37 (10) | 94 (11.1) | 60 | 9 | 37 | 11.76 | |||
2 | 6 weeks | 114 | Paliperidone: 66.7% | 2.09 (4.50) | 6.6 | 70 (5) | 91.8 (9.7) | 99 | 0 | 74 | 0 |
Placebo: 33.3% | 0 | 2.6 | 69 (3) | 94.3 (9) | 100 | 0 | 71 | 2.63 | |||
3 | 6 weeks | 627 | Olanzapine: 20.1% | 0.84 (1.04) | 2.4 | 36 (11) | 93 (10.7) | 87 | 0 | 54 | 22.22 |
Paliperidone: 59.8% | 2.46 (4.08) | 2.1 | 37 (11) | 94 (11.1) | 86 | 0 | 46 | 10.93 | |||
Placebo: 20.1% | 0 | 2.4 | 37 (11) | 94.1 (10.7) | 84 | 0 | 48 | 3.17 | |||
4 | 6 weeks | 438 | Olanzapine: 24.9% | 0.56 (1.92) | 13.8 | 40 (11) | 94.9 (12.3) | 42 | 0 | 19 | 17.43 |
Paliperidone: 51.1% | 1.68 (3.84) | 13.8 | 42 (10) | 93.2 (11.7) | 41 | 0 | 31 | 10.27 | |||
Placebo: 24% | 0 | 21.9 | 42 (11) | 93.5 (11.9) | 48 | 0 | 22 | 5.71 | |||
5 | 6 weeks | 614 | Olanzapine: 20.7% | 0.84 (0.94) | 4.7 | 37 (10) | 93.4 (12.2) | 48 | 23 | 24 | 19.69 |
Paliperidone: 59.3% | 2 (4.58) | 11.5 | 37 (11) | 92.6 (12.6) | 49 | 21 | 36 | 10.99 | |||
Placebo: 20% | 0 | 8.9 | 37 (11) | 93.8 (12.6) | 51 | 21 | 30 | 5.69 | |||
6a | 6 weeks | 316 | Pali: 66.1% | 3.52 (8.00) | 19.6 | 37 (10) | 94.2 (12.9) | 43 | 22 | 34 | 6.70 |
Placebo: 33.9% | 0 | 19.6 | 37 (11) | 91.6 (12.5) | 50 | 19 | 37 | 1.87 | |||
7a | 6 weeks | 310 | Paliperidone: 69.4% | 3.28 (4.00) | 24.2 | 38 (9) | 92.2 (13.5) | 52 | 18 | 45 | 6.98 |
Placebo: 30.6% | 0 | 28.4 | 38 (10) | 91.7 (12) | 52 | 18 | 41 | 1.05 | |||
8a | 18 months | 342 | Olanzapine: 50% | 0.84 (3.9) | 13.5 | 41 (11) | 74.3 (19) | 65 | 32 | 27 | 11.11 |
Risperidone: 50% | 0.42 (1.23) | 20.5 | 41 (11) | 76.8 (16.8) | 66 | 30 | 27 | 5.26 | |||
9b | Recurrence prevention | 408 | Paliperidone: 50.2% | 1.78 (6.67) | 10.7 | 39 (11) | 70 (18.3) | 65 | 18 | 47 | 5.85 |
Placebo: 49.8% | 0 | 10.8 | 39 (11) | 70.6 (17.6) | 66 | 18 | 45 | 2.46 | |||
10b | 53 weeks | 748 | Paliperidone: 50.7% | 4.33 (8.50) | 9 | 41 (12) | 82 (12.7) | 92 | 0 | 43 | 13.19 |
Risperidone: 49.3% | 0.38 (4.78) | 8.4 | 41 (12) | 81.2 (13.4) | 92 | 0 | 38 | 14.09 | |||
11b | 13 weeks | 387 | Paliperidone: 75.5% | 1.33 (4.00) | 15.8 | 40 (11) | 90.4 (11.3) | 40 | 41 | 32 | 12.33 |
Placebo: 24.5% | 0 | 20 | 40 (11) | 93.9 (12.9) | 38 | 41 | 27 | 9.47 | |||
12b | 13 weeks | 515 | Paliperidone: 75.5% | 1.33 (2.67) | 11.3 | 40 (11) | 90.8 (12) | 67 | 29 | 32 | 12.34 |
Placebo: 24.5% | 0 | 7.9 | 40 (11) | 90.7 (12.3) | 66 | 29 | 38 | 7.14 | |||
13b | 13 weeks | 651 | Paliperidone: 74.8% | 2 (4.00) | 7.6 | 39 (11) | 87.3 (11.5) | 53 | 31 | 32 | 11.29 |
Placebo: 25.2% | 0 | 6.7 | 39 (11) | 86.8 (10.2) | 54 | 32 | 34 | 4.27 | |||
14b | 9 weeks | 247 | Paliperidone: 66% | 1 (2.00) | 8 | 38 (10) | 94.4 (11.5) | 70 | 17 | 31 | 5.52 |
Placebo: 34% | 0 | 7.1 | 39 (11) | 95.7 (12.7) | 73 | 17 | 35 | 3.57 | |||
All studies | 5923 | Olanzapine: 9% | 0.84 (3.9) | 8.8 | 39 (11) | 87.5 (17.1) | 62 | 16 | 31 | 17.07 | |
Paliperidone: 58.8% | 2 (21.3) | 11.1 | 39 (12) | 89.3 (13.8) | 62 | 18 | 38 | 10.40 | |||
Placebo: 23.1% | 0 | 12.1 | 40 (12) | 89 (15.1) | 60 | 18 | 38 | 4.82 | |||
Risperidone: 9.1% | 0.40 (4.78) | 12.2 | 41 (12) | 79.8 (14.7) | 84 | 9 | 34 | 11.30 | |||
